Certara, Inc. CERT
Set alert
At close · Oct 30
After hours · Oct 30, 4:02 PM ET
- YTD
- +25.09%
- 1 year
- -2.99%
- Open
- 11.07
- Prev close
- 11.20
- Mkt cap
- 1.68B
- Vol
- 1.95M
- Avg vol
- 2.82M
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.65
- High
- 11.19
- Forward P/E
- 27.27
- Beta
- 1.43
- Short ratio
- 8.41
- Inst. own
- 111.12%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 8.97
- 200-d avg
- 7.26
- 1y target
- 9.17
News
5 days ago globenewswire.com
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third…
1 week ago defenseworld.net
Weave Communications (NYSE:WEAV) versus Certara (NASDAQ:CERT) Head-To-Head Comparison
Certara (NASDAQ: CERT - Get Free Report) and Weave Communications (NYSE: WEAV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the…
-
2 weeks ago benzinga.com
Keybanc Maintains Overweight on Certara, Raises Price Target to $12
Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and raises the price target from $9 to $12.
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Certara, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Certara (NASDAQ:CERT) with a Buy and raises the price target from $9 to $11.
-
3 weeks ago benzinga.com
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $7.5 to $9.
-
1 month ago benzinga.com
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
UBS analyst Kevin Caliendo downgrades Certara (NASDAQ:CERT) from Buy to Neutral and maintains the price target from $10 to $10.
1 month ago defenseworld.net
Critical Contrast: Certara (NASDAQ:CERT) versus Doximity (NYSE:DOCS)
Certara (NASDAQ: CERT - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the…
1 month ago defenseworld.net
OneMedNet (NASDAQ:ONMD) and Certara (NASDAQ:CERT) Financial Comparison
Certara (NASDAQ: CERT - Get Free Report) and OneMedNet (NASDAQ: ONMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies…
1 month ago defenseworld.net
Bank of New York Mellon Corp Purchases Shares of 731,012 Certara, Inc. $CERT
Bank of New York Mellon Corp purchased a new position in Certara, Inc. (NASDAQ: CERT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
1 month ago globenewswire.com
The Market Just Told You Which Layer Of AI Biology It Is Paying For
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the…
1 month ago defenseworld.net
Definitive Healthcare (NASDAQ:DH) & Certara (NASDAQ:CERT) Financial Comparison
Definitive Healthcare (NASDAQ: DH - Get Free Report) and Certara (NASDAQ: CERT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the…
2 months ago defenseworld.net
BlackRock Inc. Acquires New Stake in Certara, Inc. $CERT
BlackRock Inc. purchased a new position in shares of Certara, Inc. (NASDAQ: CERT) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
2 months ago seekingalpha.com
Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $6.5 to $7.5.
2 months ago seekingalpha.com
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Certara Q2 Earnings Call Highlights
Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue…
2 months ago zacks.com
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
2 months ago benzinga.com
Transcript: Certara Q2 2026 Earnings Conference Call
Certara (NASDAQ:CERT) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
-
2 months ago benzinga.com
Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est
Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 analyst estimate. Lowers FY2026 sales outlook from $395.000 million-$405.000 million to $367.000…
-
2 months ago benzinga.com
Certara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year. The…
2 months ago globenewswire.com
Certara Reports Second Quarter 2026 Financial Results
Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026…
3 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to…
3 months ago prnewswire.com
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
3 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to…
3 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to…
3 months ago globenewswire.com
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second…
3 months ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. (“Certara” or the “Company”) (NASDAQ: CERT). Such investors are advised to…
3 months ago benzinga.com
Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & More
Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silicon and advanced connectivity technologies in America.
3 months ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to contact…
3 months ago benzinga.com
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.
-
3 months ago benzinga.com
Certara Partners With NVIDIA To Advance Its Open Integrated AI Platform, Unifying Scientific Software, Regulatory Expertise, And Proprietary Datasets With AI-First, Agentic Frameworks
Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software,…
4 months ago benzinga.com
Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
US stock futures mixed, Franklin Covey Co drops 19.7% after lowering revenue guidance. Other stocks moving lower in pre-market trading.
-
5 months ago benzinga.com
Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8
Craig-Hallum analyst Matthew Hewitt maintains Certara (NASDAQ:CERT) with a Hold and lowers the price target from $10 to $8.
-
5 months ago benzinga.com
BMO Capital Maintains Market Perform on Certara, Lowers Price Target to $6
BMO Capital analyst Sean Dodge maintains Certara (NASDAQ:CERT) with a Market Perform and lowers the price target from $7 to $6.
-
5 months ago benzinga.com
Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $6.5
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $8 to $6.5.
-
5 months ago benzinga.com
Stephens & Co. Maintains Overweight on Certara, Lowers Price Target to $9
Stephens & Co. analyst Jeff Garro maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $10 to $9.
-
5 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $10
Morgan Stanley analyst Sean Laaman maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $11 to $10.
-
5 months ago benzinga.com
Baird Maintains Neutral on Certara, Lowers Price Target to $6
Baird analyst Joe Vruwink maintains Certara (NASDAQ:CERT) with a Neutral and lowers the price target from $7 to $6.
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
5 months ago benzinga.com
S&P 500 Tops 7,400 As Copper Hits Record Highs: Stock Market Today
Small caps lead a mixed Wall Street session as Trump rejects Iran's peace response, sending crude back above $97, copper to a record and silver up 7%.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
5 months ago benzinga.com
Certara Lowers FY2026 Adj EPS Guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 Est; Lowers FY2026 Sales Guidance from $418.800M-$435.552M to $395.000M-$405.000M vs $425.854M Est
Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 analyst estimate. Lowers FY2026 sales outlook from $418.800 million-$435.552 million to $395.000…
-
5 months ago benzinga.com
Certara Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $106.900M Beat $106.095M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 35.71 percent decrease over earnings of $0.14 per…
-
5 months ago benzinga.com
Altasciences And Certara Announce Strategic Partnership To Accelerate Early-Phase Development Programs
Altasciences, a fully integrated drug development solution company, andCertara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to…
6 months ago benzinga.com
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.
-
6 months ago benzinga.com
Keybanc Maintains Overweight on Certara, Lowers Price Target to $8
Keybanc analyst Brandon Nispel maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $10 to $8.
7 months ago benzinga.com
Forecasting The Future: 7 Analyst Projections For Certara
Forecasting The Future: 7 Analyst Projections For Certara
-
7 months ago benzinga.com
Barclays Downgrades Certara to Equal-Weight, Maintains Price Target to $8
Barclays analyst Luke Sergott downgrades Certara (NASDAQ:CERT) from Overweight to Equal-Weight and maintains the price target from $8 to $8.